European Journal of Molecular & Clinical Medicine

Background: Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is often asymptomatic and silent, and progresses slowly and is one of the most common causes of chronic liver disease. NAFLD affects a third of the world population with very much high prevalence among patients with diabetes mellitus, obesity, hypertension, dyslipidemia, hypothyroidism etc. The natural history of NAFLD ranges from pure steatosis to steatohepatitis (NASH) to cirrhosis and in some patientsto hepatocellular carcinoma (HCC). NAFLD has been found to be the hepatic components of metabolic syndrome which is one of the leading causes of chronic liver disease. This study aimed to determine the biochemical hepatic markers and lipid profile among NAFLD patients and their possible relationship with degrees of fatty liver and other comorbidities to aid the clinician tointervene early in order to delay the occurrence of complications associated with NAFLD.
Materials and Methods: In this analytical cross sectional study, 145 individuals aged 20–69 years referred to the Govt Medical College/ GGH Hospital Suryapet during the period from June 2021 to May 2022, were included through sequential sampling method after meeting inclusion and exclusion criteria and after taking informed consent and ethical committee approval. Serum lipid profile and Serum liver enzymes was estimated on ERBA EM 360 auto analyzer.
Results: We found significant increase in lipid parameters (TC, LDL-C, VLDL-C, and TG), liver enzymes (AST, ALT, and GGT) and decrease in HDL-C and AST/ALT (Deritis ratio) in NAFLD with type 2 DM compared to controls.
Conclusion: We conclude from our study that in obesity, dyslipidemia, hypertension, hypothyroidism and Type 2 DM the elevated liver enzymes and lipid profile could be biomarkers for the early diagnosis of NAFLD with Type 2 DM and other comorbidities.

Objective: Monoterpenes plays an essential role to fight against various diseases. Among the various monoterpenes an efficientd-Limonene plays a fundamental role to fight against hepatotoxicity caused by cancer chemotheraphy treatment. Hence the presence study is to evaluate hepatoprotective function of d-limonene against adraimycin induced hepatotoxicity.
Methods: Male albino Wistar rats were administrated with ADR (15mg/Kg body weight) in six equal injection, and the protection efficacy of d-limonene (100mg/Kg body weight) was examined with reference to tissue AST level and the pathological studies was examined by microscopic study.
Results: Rats treated with ADR results in elevated level of liver AST marker enzymes, whereasthe level of AST was controlled when administrated with d-Limonene. However Histopathological proof added more protective role of rats treated with d-limonene against hepatotoxicity.
Conclusion:ADR administration of 15mg/Kg body weight of rats increase the level of hepatotoxicity by increasing the marker enzyme activity and show severe morphological changes. The final outcome from our result suggests that d-limonene (100mg/Kg body weight) a vibrant monoterpene act as latent hepatoprotective negotiator by attenuating ADR induced hepatotoxicity

Physiological, immunogenetic, selection, technological, biotechnological, and other methods to increase the productivity of karakul sheep are used to increase their productivity, as well as biologically active substances that increase the productivity of karakul sheep.